All Stories

  1. From Discovery to Therapy: The Role of HSPB1 in HBV Persistence

    Article • Journal of Hepatology, December 2025, Elsevier

    Dr Richard Brown

  2. Seroprevalence of segmented flavi-like Alongshan virus in horses

    Article • Veterinary Microbiology, October 2025, Elsevier

    Dr Richard Brown

  3. From zoonotic spillover to endemicity: the broad determinants of human coronavirus tropism

    Article • mBio, September 2025, ASM Journals

    Dr Richard Brown

  4. Mycophenolic acid treatment drives the emergence of novel SARS-CoV-2 variants

    Article • Proceedings of the National Academy of Sciences, July 2025, Proceedings of the National Academy of Sciences

    Toni Luise Meister, Dr Richard Brown

  5. Adapted hepatitis C virus clone infects innate immunity-deficient mouse hepatocytes with minimal human HCV entry factors

    Article • JHEP Reports, May 2025, Elsevier

    Dr Richard Brown

  6. Differential efficacy of first licensed western vaccines protecting without immunopathogenesis Wuhan-1-challenged hamsters from severe COVID-19

    Article • npj Vaccines, March 2025, Springer Science + Business Media

    Dr Richard Brown

  7. The glutamate receptor antagonist ifenprodil inhibits hepatitis E virus infection

    Article • Antimicrobial Agents and Chemotherapy, November 2024, ASM Journals

    Dr Richard Brown

  8. MicroRNAs modulate SARS‐CoV‐2 infection of primary human hepatocytes by regulating the entry factors ACE2 and TMPRSS2

    Article • Liver International, August 2024, Wiley

    Dr Richard Brown

  9. Inactivation of yellow fever virus by WHO-recommended hand rub formulations and surface disinfectants

    Article • PLoS Neglected Tropical Diseases, June 2024, PLOS

    Dr Richard Brown

  10. Host determinants and responses underlying SARS-CoV-2 liver tropism

    Article • Current Opinion in Microbiology, June 2024, Elsevier

    Dr Richard Brown

  11. TMPRSS2-mediated SARS-CoV-2 uptake boosts innate immune activation, enhances cytopathology, and drives convergent virus evolution

    Article • Proceedings of the National Academy of Sciences, May 2024, Proceedings of the National Academy of Sciences

    Dr Richard Brown

  12. Targeting cellular cathepsins inhibits hepatitis E virus entry

    Article • Hepatology, May 2024, Wolters Kluwer Health

    Dr Richard Brown

  13. Unraveling the dynamics of hepatitis C virus adaptive mutations and their impact on antiviral responses in primary human hepatocytes

    Article • Journal of Virology, March 2024, ASM Journals

    Dr Richard Brown

  14. Repurposing screen identifies novel candidates for broad-spectrum coronavirus antivirals and druggable host targets

    Article • Antimicrobial Agents and Chemotherapy, March 2024, ASM Journals

    Dr Richard Brown

  15. Spatiotemporal analysis of SARS-CoV-2 infection reveals an expansive wave of monocyte-derived macrophages associated with vascular damage and virus clearance in hamster lungs

    Article • Microbiology Spectrum, January 2024, ASM Journals

    Dr Richard Brown

  16. Productive infection of primary human hepatocytes with SARS-CoV-2 induces antiviral and proinflammatory responses

    Article • Gut, December 2023, BMJ

    Dr Richard Brown

  17. Mouse Liver-Expressed Shiftless Is an Evolutionarily Conserved Antiviral Effector Restricting Human and Murine Hepaciviruses

    Article • Microbiology Spectrum, August 2023, ASM Journals

    Dr Richard Brown

  18. Spatiotemporal analysis of SARS-CoV-2 infection reveals an expansive wave of monocyte-derived macrophages associated with vascular damage and virus clearance in hamster lungs

    Article • March 2023, Cold Spring Harbor Laboratory Press

    Dr Richard Brown

  19. SARS-CoV-2 entry route impacts a range of downstream viral and cellular processes

    Article • August 2022, Cold Spring Harbor Laboratory Press

    Dr Richard Brown

  20. Vaccine-associated enhanced respiratory pathology in COVID-19 hamsters after TH2-biased immunization

    Article • Cell Reports, August 2022, Elsevier

    Dr. Michael D. Muehlebach, Dr Richard Brown

  21. The Human Liver-Expressed Lectin CD302 Restricts Hepatitis C Virus Infection

    Article • Journal of Virology, April 2022, ASM Journals

    Dr Richard Brown

  22. Intra-host analysis of hepaciviral glycoprotein evolution reveals signatures associated with viral persistence and clearance

    Article • Virus Evolution, January 2022, Oxford University Press (OUP)

    Dr Richard Brown

  23. In contrast to TH2-biased approaches, TH1 COVID-19 vaccines protect Syrian hamsters from severe disease in the absence of dexamethasone-treatable vaccine-associated enhanced respiratory pathology

    Article • December 2021, Cold Spring Harbor Laboratory Press

    Dr Richard Brown

  24. Generation of hiPSC-derived low threshold mechanoreceptors containing axonal termini resembling bulbous sensory nerve endings and expressing Piezo1 and Piezo2

    Article • Stem Cell Research, October 2021, Elsevier

    Dr Richard Brown

  25. Strategies to Inhibit Hepatitis B Virus at the Transcript Level

    Article • Viruses, July 2021, MDPI AG

    Dr Richard Brown

  26. Initial Hepatitis C Virus Infection of Adult Hepatocytes Triggers a Temporally Structured Transcriptional Program Containing Diverse Pro- and Antiviral Elements

    Article • Journal of Virology, April 2021, ASM Journals

    Dr Richard Brown

  27. Single-cell analysis of arthritogenic alphavirus-infected human synovial fibroblasts links low abundance of viral RNA to induction of innate immunity and arthralgia-associated gene expression

    Article • Emerging Microbes & Infections, January 2021, Taylor & Francis

    Dr Richard Brown

  28. Liver-expressed Cd302 and Cr1l limit hepatitis C virus cross-species transmission to mice

    Article • Science Advances, November 2020, American Association for the Advancement of Science

    Dr Richard Brown

  29. C19orf66 is an interferon-induced inhibitor of HCV replication that restricts formation of the viral replication organelle

    Article • Journal of Hepatology, September 2020, Elsevier

    Dr Richard Brown

  30. Efficient acute and chronic infection of stem cell-derived hepatocytes by hepatitis C virus

    Article • Gut, February 2020, BMJ

    Dr Richard Brown

  31. Yellow Fever: Integrating Current Knowledge with Technological Innovations to Identify Strategies for Controlling a Re-Emerging Virus

    Article • Viruses, October 2019, MDPI AG

    Dr Richard Brown

  32. Identification of Keratin 23 as a Hepatitis C Virus-Induced Host Factor in the Human Liver

    Article • Cells, June 2019, MDPI AG

    Dr Richard Brown

  33. A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors

    Article • Journal of Hepatology, June 2019, Elsevier

    Dr Richard Brown

  34. Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants

    Article • Journal of Hepatology, April 2019, Elsevier

    Dr Richard Brown

  35. Hepatitis C Virus

    Article • Trends in Microbiology, April 2019, Elsevier

    Dr Richard Brown

  36. Immunization with a synthetic consensus hepatitis C virus E2 glycoprotein ectodomain elicits virus-neutralizing antibodies

    Article • Antiviral Research, December 2018, Elsevier

    Dr Richard Brown

  37. Molecular characteristics and successful management of a respiratory syncytial virus outbreak among pediatric patients with hemato-oncological disease

    Article • Antimicrobial Resistance and Infection Control, February 2018, Springer Science + Business Media

    Dr Richard Brown

  38. Hepatitis C Virus Strain-Dependent Usage of Apolipoprotein E Modulates Assembly Efficiency and Specific Infectivity of Secreted Virions

    Article • Journal of Virology, June 2017, ASM Journals

    Dr Richard Brown

  39. Immune protection against reinfection with nonprimate hepacivirus

    Article • Proceedings of the National Academy of Sciences, March 2017, Proceedings of the National Academy of Sciences

    Dr Richard Brown

  40. Exacerbation of hepatitis E virus infection during anti-TNFα treatment

    Article • Joint Bone Spine, March 2017, Elsevier

    Dr Richard Brown

  41. Tracking HCV protease population diversity during transmission and susceptibility of founder populations to antiviral therapy

    Article • Antiviral Research, March 2017, Elsevier

    Dr Richard Brown

  42. Hepacivirus NS3/4A Proteases Interfere with MAVS Signaling in both Their Cognate Animal Hosts and Humans: Implications for Zoonotic Transmission

    Article • Journal of Virology, December 2016, ASM Journals

    Dr Richard Brown

  43. Mutagenic Effects of Ribavirin on Hepatitis E Virus—Viral Extinction versus Selection of Fitness-Enhancing Mutations

    Article • Viruses, October 2016, MDPI AG

    Dr Richard Brown

  44. Vertical transmission of hepatitis C virus-like non-primate hepacivirus in horses

    Article • Journal of General Virology, October 2016, Society for General Microbiology

    Dr Richard Brown

  45. Hepatitis E Virus (HEV) ORF2 Antigen Levels Differentiate Between Acute and Chronic HEV Infection

    Article • The Journal of Infectious Diseases, May 2016, Oxford University Press (OUP)

    Dr Richard Brown

  46. In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome

    Article • Gut, May 2016, BMJ

    Dr Richard Brown

  47. Ion Channel Function and Cross-Species Determinants in Viral Assembly of Nonprimate Hepacivirus p7

    Article • Journal of Virology, May 2016, ASM Journals

    Dr Richard Brown

  48. A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance

    Article • Journal of Virology, April 2016, ASM Journals

    Dr Richard Brown

  49. Flunarizine prevents hepatitis C virus membrane fusion in a genotype‐dependent manner by targeting the potential fusion peptide within E1

    Article • Hepatology, October 2015, Wolters Kluwer Health

    Dr Richard Brown

  50. Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice

    Article • Gut, August 2015, BMJ

    Dr Richard Brown

  51. Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design

    Article • Viruses, July 2015, MDPI AG

    Dr Richard Brown

  52. Clinical course of infection and viral tissue tropism of hepatitis C virus-like nonprimate hepaciviruses in horses

    Article • Hepatology, January 2015, Wiley

    Dr Richard Brown

  53. Development of a high-throughput pyrosequencing assay for monitoring temporal evolution and resistance associated variant emergence in the Hepatitis C virus protease coding-region

    Article • Antiviral Research, October 2014, Elsevier

    Ralf Bartenschlager, Dr Richard Brown

  54. Incorporation of primary patient-derived glycoproteins into authentic infectious hepatitis C virus particles

    Article • Hepatology, August 2014, Wolters Kluwer Health

    Dr Richard Brown

  55. Natural reservoirs for homologs of hepatitis C virus

    Article • Emerging Microbes & Infections, January 2014, Taylor & Francis

    Dr Richard Brown

  56. Recombinant Human L-Ficolin Directly Neutralizes Hepatitis C Virus Entry

    Article • Journal of Innate Immunity, January 2014, Karger Publishers

    Dr Richard Brown

  57. Use of short tandem repeat fingerprinting to validate sample origins in hepatitis C virus molecular epidemiology studies

    Article • Journal of General Virology, January 2014, Society for General Microbiology

    Dr Richard Brown

  58. Cell entry, efficient RNA replication, and production of infectious hepatitis C virus progeny in mouse liver-derived cells

    Article • Hepatology, November 2013, Wolters Kluwer Health

    Dr Richard Brown

  59. Analysis of Serine Codon Conservation Reveals Diverse Phenotypic Constraints on Hepatitis C Virus Glycoprotein Evolution

    Article • Journal of Virology, October 2013, ASM Journals

    Dr Richard Brown

  60. Mannan binding lectin-associated serine protease 1 is induced by hepatitis C virus infection and activates human hepatic stellate cells

    Article • Clinical & Experimental Immunology, October 2013, Oxford University Press (OUP)

    Dr Richard Brown

  61. Characterization of Hepatitis C Virus Intra- and Intergenotypic Chimeras Reveals a Role of the Glycoproteins in Virus Envelopment

    Article • Journal of Virology, October 2013, ASM Journals

    Dr Richard Brown

  62. An Alpaca Nanobody Inhibits Hepatitis C Virus Entry And Cell-To-Cell Transmission

    Article • Hepatology, September 2013, Wolters Kluwer Health

    Dr Richard Brown

  63. Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells

    Article • Gut, July 2013, BMJ

    Dr Richard Brown

  64. Hepatitis C Virus Envelope Glycoprotein Fitness Defines Virus Population Composition following Transmission to a New Host

    Article • Journal of Virology, August 2012, ASM Journals

    Dr Richard Brown

  65. Naturally Occurring Antibodies That Recognize Linear Epitopes in the Amino Terminus of the Hepatitis C Virus E2 Protein Confer Noninterfering, Additive Neutralization

    Article • Journal of Virology, December 2011, ASM Journals

    Dr Richard Brown

  66. Intercompartmental Recombination of HIV-1 Contributes to env Intrahost Diversity and Modulates Viral Tropism and Sensitivity to Entry Inhibitors

    Article • Journal of Virology, April 2011, ASM Journals

    Dr Richard Brown

  67. Hepatitis C Patient-Derived Glycoproteins Exhibit Marked Differences in Susceptibility to Serum Neutralizing Antibodies: Genetic Subtype Defines Antigenic but Not Neutralization Serotype

    Article • Journal of Virology, February 2011, ASM Journals

    Dr Richard Brown

  68. Acute Hepatitis C Virus Infection: A Dynamic—and Challenging—Concept

    Article • The Journal of Infectious Diseases, December 2010, Oxford University Press (OUP)

    Dr Richard Brown

  69. A case of hepatitis C virus transmission acquired through sharing a haemodialysis machine

    Article • Clinical Kidney Journal, October 2010, Oxford University Press (OUP)

    Dr Richard Brown

  70. Variation in the biological properties of HIV-1 R5 envelopes: implications of envelope structure, transmission and pathogenesis

    Article • Future Virology, July 2010, Future Medicine

    Dr Richard Brown

  71. Variation in HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block envelope: CD4 interactions but not with sensitivity to other entry inhibitors

    Article • Retrovirology, January 2008, Springer Science + Business Media

    Dr Richard Brown

  72. Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33

    Article • Journal of General Virology, November 2007, Society for General Microbiology

    Dr Richard Brown

  73. Cross-genotype characterization of genetic diversity and molecular adaptation in hepatitis C virus envelope glycoprotein genes

    Article • Journal of General Virology, February 2007, Society for General Microbiology

    Dr Richard Brown

  74. Identification of Conserved Residues in the E2 Envelope Glycoprotein of the Hepatitis C Virus That Are Critical for CD81 Binding

    Article • Journal of Virology, September 2006, ASM Journals

    Dr Richard Brown

  75. Non-Macrophage-Tropic Human Immunodeficiency Virus Type 1 R5 Envelopes Predominate in Blood, Lymph Nodes, and Semen: Implications for Transmission and Pathogenesis

    Article • Journal of Virology, July 2006, ASM Journals

    Dr Richard Brown

  76. Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33

    Article • Hepatology, January 2006, Wolters Kluwer Health

    Ralf Bartenschlager, Dr Richard Brown

  77. Evolutionary dynamics of hepatitis C virus envelope genes during chronic infection

    Article • Journal of General Virology, July 2005, Society for General Microbiology

    Dr Richard Brown